IgA Vasculitis Developing during Trastuzumab Emtansine Therapy for HER2-positive Breast Cancer

Read full text
Authors: Nanami Watanabe, Shun Yoshida, Keiichi Osano, Kie Ohkoshi, Toshihisa Ishii, Makiko Konishi, Haruka Nakada, Naoki Ashizawa, Yuko Nakayama, Hiroshi Mitsui, Kazuya Takahashi, Ayumu Nakashima
Cited by: 2
References: 18

Abstract

An elderly woman undergoing trastuzumab emtansine (T-DM1) treatment for HER2-positive breast cancer visited our department with purpura, hematuria, proteinuria, and a decreased renal function. A skin biopsy revealed leukocytoclastic vasculitis with immunoglobulin A (IgA) deposition, confirming the diagnosis of IgA vasculitis. Owing to active renal lesions, the patient was treated with prednisolone and cyclophosphamide, which resulted in clinical remission. A renal biopsy performed five months post-treatment revealed persistent mild proliferative glomerulonephritis with fibrotic crescent formation. This case was considered to have T-DM1-associated IgA vasculitis. Although rare, an awareness of the possibility of serious adverse effects associated with drug administration is important.

Fields of Study & Subjects

HER2/EGFR in Cancer Research Vasculitis and related conditions Monoclonal and Polyclonal Antibodies Research

Publication details

Journal / source
Internal Medicine
Publisher
Japanese Society of Internal Medicine
Publication date
1 January 2026
Language
EN